Identification of Targets and New Developments in the Treatment of Multiple Sclerosis &Ndash; Focus on Cladribine

Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s6627
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Update and Developments in the Treatment of Glioblastoma Multiforme &Ndash; Focus on Bevacizumab

Pharmacogenomics and Personalized Medicine
Molecular MedicinePharmacology
2010English

New Developments in the Management of Opioid Dependence: Focus on Sublingual Buprenorphine–naloxone

Substance Abuse and Rehabilitation
2015English

New Developments in the Treatment of Chemotherapy-Induced Neutropenia: Focus on Balugrastim

Therapeutics and Clinical Risk Management
2016English

Cladribine for Highly Active Relapsing Multiple Sclerosis

Prescriber
Pharmacology
2018English

New Advancements and Developments in Treatment of Renal Cell Carcinoma: Focus on Pazopanib

OncoTargets and Therapy
OncologyPharmacology
2010English

E-Health 2.0 Developments in Treatment and Research in Multiple Sclerosis

2012English

New Agents for the Treatment of Hepatitis C Virus &Ndash; Focus on Telaprevir

Virus Adaptation and Treatment
VirologyInfectious DiseasesImmunology
2012English

New Developments in the Treatment of Advanced Squamous Cell Lung Cancer: Focus on Afatinib

OncoTargets and Therapy
OncologyPharmacology
2017English

Pnd62 - Cost-Effectiveness of Cladribine Tablets in the Treatment of Patients With Highly Active Relapsing Multiple Sclerosis in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy